Daily Progress: Wave Life Sciences Ltd (WVE) Gain 2.15%, Closing at $7.14

Nora Barnes

Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.

In the latest session, Wave Life Sciences Ltd (NASDAQ: WVE) closed at $7.14 up 2.15% from its previous closing price of $6.99. In other words, the price has increased by $2.15 from its previous closing price. On the day, 2.6 million shares were traded. WVE stock price reached its highest trading level at $7.24 during the session, while it also had its lowest trading level at $6.93.

Ratios:

For a deeper understanding of Wave Life Sciences Ltd’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.51 and its Current Ratio is at 2.51. In the meantime, Its Debt-to-Equity ratio is 0.15 whereas as Long-Term Debt/Eq ratio is at 0.09.

Upgrades & Downgrades

In the most recent recommendation for this company, Wells Fargo on October 20, 2025, initiated with a Overweight rating and assigned the stock a target price of $18.

On August 04, 2025, Canaccord Genuity started tracking the stock assigning a Buy rating and target price of $19.

On July 28, 2025, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $24.Oppenheimer initiated its Outperform rating on July 28, 2025, with a $24 target price.

Insider Transactions:

Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 13 ’25 when Rawcliffe Adrian sold 16,115 shares for $6.79 per share. The transaction valued at 109,421 led to the insider holds 12,700 shares of the business.

RA CAPITAL MANAGEMENT, L.P. bought 1,000 shares of WVE for $6,688 on Nov 13 ’25. The Director now owns 18,203,009 shares after completing the transaction at $6.69 per share. On Nov 13 ’25, another insider, ADRIAN RAWCLIFFE, who serves as the Director of the company, bought 16,115 shares for $6.96 each.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, WVE now has a Market Capitalization of 1193677952 and an Enterprise Value of 1025105920. For the stock, the TTM Price-to-Sale (P/S) ratio is 10.93 while its Price-to-Book (P/B) ratio in mrq is 9.19. Its current Enterprise Value per Revenue stands at 9.385 whereas that against EBITDA is -7.74.

Stock Price History:

The Beta on a monthly basis for WVE is -1.68, which has changed by -0.515928 over the last 52 weeks, in comparison to a change of 0.12415576 over the same period for the S&P500. Over the past 52 weeks, WVE has reached a high of $15.72, while it has fallen to a 52-week low of $5.28. The 50-Day Moving Average of the stock is -4.18%, while the 200-Day Moving Average is calculated to be -8.36%.

Shares Statistics:

For the past three months, WVE has traded an average of 2.74M shares per day and 2093630 over the past ten days. A total of 160.29M shares are outstanding, with a floating share count of 134.97M. Insiders hold about 19.27% of the company’s shares, while institutions hold 82.40% stake in the company. Shares short for WVE as of 1763078400 were 15407887 with a Short Ratio of 5.63, compared to 1760486400 on 13141809. Therefore, it implies a Short% of Shares Outstanding of 15407887 and a Short% of Float of 12.2600004.

Earnings Estimates

Its stock is currently analyzed by 11.0 different market analysts. The consensus estimate for the next quarter is -$0.31, with high estimates of -$0.27 and low estimates of -$0.35.

Analysts are recommending an EPS of between -$1.0 and -$1.27 for the fiscal current year, implying an average EPS of -$1.16. EPS for the following year is -$1.16, with 12.0 analysts recommending between -$0.65 and -$1.62.

Revenue Estimates

A total of 14 analysts believe the company’s revenue will be $17.63M this quarter.It ranges from a high estimate of $47M to a low estimate of $7.61M. As of. The current estimate, Wave Life Sciences Ltd’s year-ago sales were $83.75M

A total of 14 analysts have provided revenue estimates for WVE’s current fiscal year. The highest revenue estimate was $72.5M, while the lowest revenue estimate was $33.09M, resulting in an average revenue estimate of $43.96M. In the same quarter a year ago, actual revenue was $108.3M

DwinneX
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.